All In Biotech

Drug Trial Radar · NCT02859519

A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

Last checked: Nov 19, 2026Latest source record: Dec 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 365 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

365

Actual

Start

Oct 2016

Primary completion

Nov 13, 2019

Study completion Nov 13, 2019

Sponsor

Lead sponsor
Moberg Pharma ABIndustry
Sponsor type
Industry
First posted
Aug 9, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of topical MOB015B in patients with mild to moderate distal subungual onychomycosis (DSO). The secondary objective is to evaluate the safety of topical MOB015B in patients with mild to moderate DSO.

Conditions

  • Distal Subungual Onychomycosis

Interventions

  • MOB015BDrug

    MOB015B - Terbinafine hydrochloride (HCl) 10%, topical solution

  • MOB015B VehicleDrug

    MOB015B Vehicle without the active ingredient Terbinafine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subjects with complete cure of the target toe nail at Week 52Time frame: Week 52

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Multiple Locations, California

  • Site not named

    Multiple Locations, Florida

  • Site not named

    Multiple Locations, Idaho

  • Site not named

    Rolling Meadows, Illinois

  • Site not named

    Fridley, Minnesota

  • Site not named

    Multiple Locations, New Jersey

  • Site not named

    Multiple Locations, Oregon

  • Site not named

    Multiple Locations, Texas

  • Site not named

    Multiple Locations, Virginia

  • Site not named

    Multiple Locations, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.